Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Standards Provision In Cures Bill Could Speed Up 510(k) Clearances

Executive Summary

Under a provision in the 21st Century Cures bill, which is accelerating towards enactment, FDA may need to consider recognizing more standards, which could speed up review times for 510(k)s. But it is also likely to add a burden for the agency.

Advertisement

Related Content

US FDA: 510(k)-Exempt Class II Devices Should Withdraw Applications
21st Century Cures Implementation: Device Provision Updates
US FDA Seeks Input On Standing Up Conformity Assessment Pilot
User-Fee Facts: 10 Key Medtech Details From US FDA Agreements
FDA 'Cures' Fund Breakdown: Breakthrough Devices, HDEs, IRB Flexibility And More
Senate, House Panels Release Clean Device User-Fee Discussion Draft
Must-Do Guidance Development: What's On Tap From Cures, MDUFA IV
21st Century Cures: Device Provisions
Senate Poised To Vote On Cures Bill; Headed To Likely Enactment This Term
Real-World Evidence User-Fee Funding Praised At FDA Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

MT104158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel